REGENEREX PHARMA, INC. (RGPX) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
5348 VEGAS DRIVE, SUITE 177 LAS VEGAS, NV 89108 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2025 MRQ | 3/31/2025 | 12/31/2024 MRQ | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 653 | 0 | 0 | 1 | 3 | 7 | |||
| Cash and cash equivalent | 653 | 0 | 0 | 1 | 3 | 7 | |||
| Prepaid expense | 0 | 1 | 3 | 5 | 1 | ||||
| Total current assets: | 653 | 1 | 3 | 1 | 8 | 8 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 604 | 641 | 756 | ||||||
| Property, plant and equipment | 2 | 2 | 4 | 1 | |||||
| Intangible assets, net (including goodwill) | (31) | (31) | 1 | 4 | 7 | 2 | |||
| Intangible assets, net (excluding goodwill) | (31) | (31) | 1 | 4 | 7 | 2 | |||
| Other undisclosed noncurrent assets | 34 | 34 | 2 | 0 | |||||
| Total noncurrent assets: | 610 | 646 | 764 | 5 | 7 | 2 | |||
| TOTAL ASSETS: | 1,263 | 647 | 767 | 7 | 15 | 10 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 286 | 327 | 214 | 201 | 376 | 340 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | ✕ | ✕ | 221 | 221 | ||
| Accounts payable | 198 | 185 | 117 | 75 | 63 | 48 | |||
| Accrued liabilities | 88 | 142 | 97 | 126 | 92 | 71 | |||
| Debt | 2,824 | 2,824 | 2,400 | 223 | 153 | 150 | |||
| Due to related parties | ✕ | ✕ | ✕ | ✕ | 132 | 132 | 131 | ||
| Other undisclosed current liabilities | 1,813 | 2,009 | 1,229 | 221 | |||||
| Total current liabilities: | 4,924 | 5,160 | 3,843 | 777 | 660 | 621 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 184 | ||||||||
| Long-term debt, excluding current maturities | 184 | ||||||||
| Liabilities, other than long-term debt | 496 | 541 | 682 | ||||||
| Operating lease, liability | 496 | 541 | 682 | ||||||
| Other undisclosed noncurrent liabilities | 119 | 353 | 340 | 224 | |||||
| Total noncurrent liabilities: | 496 | 541 | 985 | 353 | 340 | 224 | |||
| Total liabilities: | 5,419 | 5,701 | 4,829 | 1,129 | 1,001 | 845 | |||
| Equity | |||||||||
| Equity, attributable to parent | (4,156) | (5,054) | (4,062) | (1,123) | (986) | (835) | |||
| Common stock | 281 | 278 | 278 | 277 | 277 | 127 | |||
| Additional paid in capital | 3,706 | 1,400 | 1,276 | 672 | 672 | 777 | |||
| Accumulated deficit | (8,143) | (6,733) | (5,616) | (2,072) | (1,935) | (1,739) | |||
| Total equity: | (4,156) | (5,054) | (4,062) | (1,123) | (986) | (835) | |||
| TOTAL LIABILITIES AND EQUITY: | 1,263 | 647 | 767 | 7 | 15 | 10 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2025 TTM | 3/31/2025 | 12/31/2024 TTM | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 2 | |||||||
| Cost of revenue | (247) | |||||||
| Gross profit: | (245) | |||||||
| Operating expenses | (1,826) | (1,105) | (3,466) | (96) | (126) | (61) | ||
| Operating loss: | (1,826) | (1,105) | (3,466) | (96) | (126) | (306) | ||
| Nonoperating expense | (701) | (305) | (78) | (41) | (64) | (48) | ||
| Gain (loss), foreign currency transaction, before tax | 6 | 9 | 3 | 26 | (5) | (5) | ||
| Other nonoperating expense | (384) | |||||||
| Interest and debt expense | (25) | (81) | (67) | (59) | (43) | |||
| Other undisclosed income from continuing operations before equity method investments, income taxes | ||||||||
| Loss from continuing operations before income taxes: | (2,527) | (1,435) | (3,624) | (204) | (249) | (397) | ||
| Other undisclosed income from continuing operations | 67 | 59 | ||||||
| Loss from continuing operations: | (2,527) | (1,435) | (3,624) | (137) | (190) | (397) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | ✕ | (196) | (397) | |
| Loss from discontinued operations | (6) | |||||||
| Other undisclosed net income | 750 | |||||||
| Net income (loss): | (2,527) | (1,435) | (3,624) | (137) | (196) | 354 | ||
| Other undisclosed net income (loss) attributable to parent | 25 | 81 | ||||||
| Net income (loss) available to common stockholders, diluted: | (2,527) | (1,409) | (3,544) | (137) | (196) | 354 | ||
Comprehensive Income ($ in thousands)
| 9/30/2025 TTM | 3/31/2025 | 12/31/2024 TTM | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (2,527) | (1,435) | (3,624) | (137) | (196) | 354 | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (2,527) | (1,435) | (3,624) | (137) | (196) | 354 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.